TDLR: In 2011 scientists took a treatment of extract from the Purple Pitcher plant (Sarracenia purpurea) used to treat smallpox in 1860s and evaluated it in the lab (in vitro) to check for effectiveness. And it worked! I have purchased some in case "the pox" gets dropped on my house and I need to do a real life (in vivo) evaluation.

Note that all "poxes" are DNA-based replicating infections. This is different than the cold and Corona viruses which appear to be RNA-replicating infections which are all easily defeated with green tea extract + zinc picolinate (or other zinc ionophore treatment combo).

You can get Sarracenia purpurea here in extract form for around $30 including shipping and tax: https://amishways.com/product-category/extracts/

Extracts can be more potent than tinctures due to higher concentration. SHAKE WELL before use!

Tincture vs Extract: https://www.khromaherbs.com/blogs/news/tincture-vs-extract

In Vitro Characterization of a Nineteenth-Century Therapy for Smallpox

Received September 27, 2011; Accepted February 1, 2012; Published March 9, 2012

ABSTRACT

In the nineteenth century, smallpox ravaged through the United States and Canada. At this time, a botanical preparation, derived from the carnivorous plant Sarracenia purpurea, was proclaimed as being a successful therapy for smallpox infections. The work described characterizes the antipoxvirus activity associated with this botanical extract against vaccinia virus, monkeypox virus and variola virus, the causative agent of smallpox. Our work demonstrates the in vitro characterization of Sarracenia purpurea as the first effective inhibitor of poxvirus replication at the level of early viral transcription. With the renewed threat of poxvirus-related infections, our results indicate Sarracenia purpurea may act as another defensive measure against Orthopoxvirus infections.

Don't call it "a cure" to avoid getting in trouble with FDA, just call it "an inhibitor".

PDF https://pdfs.semanticscholar.org/8575/a23ac1f2d230c9853ea7520f5289e470ff85.pdf

The results in Fig. 1e suggest that cidofovir and S. purpurea are acting on different targets in the VACV replication cycle and that S. purpurea may be inhibiting virus replication early in the replication cycle prior to the induction of CPE.

-from page 3

To further understand the antipoxvirus activity associated with S. purpurea, we decided to analyze the capability of S. purpurea to prevent the replication of more virulent members of the Orthopoxvirus genus, namely monkeypox virus (MPXV) and variola virus (VARV).

When treated with the extract at 0 or 15 minutes post infection, S. purpurea treatment prevented the accumulation of the MPXV-F3L protein, whereas high levels of MPXV-F3L were detected in the both the untreated and carrier treated cells (Fig. 4a).

In addition, we also determined that S. purpurea treatment effectively inhibited rabbitpox virus early protein accumulation (data not shown).

-from page 5

Authors:

William Arndt1 , Chandra Mitnik1 , Karen L. Denzler1 , Stacy White1 , Robert Waters1,2, Bertram L. Jacobs1, Yvan Rochon2,3, Victoria A. Olson4 , Inger K. Damon4 , Jeffrey O. Langland1,2* 1 Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America, 2 Department of Naturopathic Research, Southwest College of Naturopathic Medicine, Tempe, Arizona, United States of America, 3Herbal Vitality, Inc., Sedona, Arizona, United States of America, 4Division of Viral and Rickettsial Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America